Skip to main content
Erschienen in: Tumor Biology 8/2014

01.08.2014 | Research Article

Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma

verfasst von: Taiwu Xiao, Li Zhang, Lei Chen, Guozhen Liu, Zhenjun Feng, Lei Gao

Erschienen in: Tumor Biology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

T cell immunoglobulin- and mucin-domain-containing molecule 3 (Tim-3) plays a critical role in immune tolerance by suppressing the activation and proliferation of T cells. The purpose of this study was to investigate the effect of Tim-3 on the development of diffuse large B cell lymphoma (DLBCL). A total of 40 newly diagnosed DLBCL patients and 30 healthy donors were recruited. Tim-3 expression on peripheral CD4+ T and CD8+ T cells was analyzed by flow cytometry. Data showed that expression of Tim-3 was significantly increased on both CD4+ and CD8+ T cells in DLBCL patients than in healthy controls (P < 0.001 and P < 0.001, respectively). Also, level of Tim-3 on CD4+ T cells was positively correlated with CD8+ T cells in patients (P < 0.001). Further analyses revealed that patients with advanced tumor stages had elevated Tim-3 expression on CD4+ and CD8+ T cells compared to those with primary tumor stages. In addition, levels of Tim-3 on CD4+ and CD8+ T cells were significantly elevated in DLBCL patients with bone marrow involvement or B symptoms. Our results suggest that Tim-3 is involved in the development of DLBCL.
Literatur
1.
Zurück zum Zitat Montgomery ND, Fedoriw Y. Pathology consultation on intermediate-to-large B-cell lymphomas. Am J Clin Pathol. 2014;141:305–17.PubMedCrossRef Montgomery ND, Fedoriw Y. Pathology consultation on intermediate-to-large B-cell lymphomas. Am J Clin Pathol. 2014;141:305–17.PubMedCrossRef
2.
Zurück zum Zitat Puvvada S, Kendrick S, Rimsza L. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet. 2013;206:257–65.PubMedCrossRef Puvvada S, Kendrick S, Rimsza L. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet. 2013;206:257–65.PubMedCrossRef
3.
Zurück zum Zitat Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P, et al. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 2014;34:557–64.PubMed Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P, et al. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 2014;34:557–64.PubMed
4.
Zurück zum Zitat Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012;24:213–6.PubMedCrossRef Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012;24:213–6.PubMedCrossRef
5.
Zurück zum Zitat Kikushige Y, Akashi K. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Ann N Y Acad Sci. 2012;1266:118–23.PubMedCrossRef Kikushige Y, Akashi K. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Ann N Y Acad Sci. 2012;1266:118–23.PubMedCrossRef
6.
Zurück zum Zitat Kozlowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene. 2013;525:200–7.PubMedCrossRef Kozlowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene. 2013;525:200–7.PubMedCrossRef
7.
Zurück zum Zitat Larsson M, Shankar EM, Che KF, Saeidi A, Ellegard R, et al. Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology. 2013;10:31.PubMedCentralPubMedCrossRef Larsson M, Shankar EM, Che KF, Saeidi A, Ellegard R, et al. Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology. 2013;10:31.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Li X, Zhao YQ, Li CW, Yuan FL. T cell immunoglobulin-3 as a new therapeutic target for rheumatoid arthritis. Expert Opin Ther Targets. 2012;16:1145–9.PubMedCrossRef Li X, Zhao YQ, Li CW, Yuan FL. T cell immunoglobulin-3 as a new therapeutic target for rheumatoid arthritis. Expert Opin Ther Targets. 2012;16:1145–9.PubMedCrossRef
9.
Zurück zum Zitat Li Z, Ju Z, Frieri M. The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity. Allergy Asthma Proc. 2013;34:e21–6.PubMedCrossRef Li Z, Ju Z, Frieri M. The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity. Allergy Asthma Proc. 2013;34:e21–6.PubMedCrossRef
10.
Zurück zum Zitat Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011;32:345–9.PubMedCentralPubMedCrossRef Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011;32:345–9.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Bai J, Li X, Tong D, Shi W, Song H, et al. T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer. Tumour Biol. 2013;34:805–9.PubMedCrossRef Bai J, Li X, Tong D, Shi W, Song H, et al. T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer. Tumour Biol. 2013;34:805–9.PubMedCrossRef
12.
Zurück zum Zitat Gao X, Zhu Y, Li G, Huang H, Zhang G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7:e30676.PubMedCentralPubMedCrossRef Gao X, Zhu Y, Li G, Huang H, Zhang G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7:e30676.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Zhuang X, Zhang X, Xia X, Zhang C, Liang X, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 2012;137:978–85.PubMedCrossRef Zhuang X, Zhang X, Xia X, Zhang C, Liang X, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 2012;137:978–85.PubMedCrossRef
14.
Zurück zum Zitat Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207:2175–86.PubMedCentralPubMedCrossRef Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207:2175–86.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19:1225–31.PubMedCentralPubMedCrossRef Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19:1225–31.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol. 2013;190:4899–909.PubMedCentralPubMedCrossRef Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol. 2013;190:4899–909.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Liberal R, Grant CR, Holder BS, Ma Y, Mieli-Vergani G, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology. 2012;56:677–86.PubMedCrossRef Liberal R, Grant CR, Holder BS, Ma Y, Mieli-Vergani G, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology. 2012;56:677–86.PubMedCrossRef
18.
Zurück zum Zitat Sakhdari A, Mujib S, Vali B, Yue FY, MacParland S, et al. Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One. 2012;7:e40146.PubMedCentralPubMedCrossRef Sakhdari A, Mujib S, Vali B, Yue FY, MacParland S, et al. Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One. 2012;7:e40146.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell Biol. 2013;32:648–53.PubMedCrossRef Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell Biol. 2013;32:648–53.PubMedCrossRef
20.
Zurück zum Zitat Han S, Feng S, Xu L, Shi W, Wang X, et al. Tim-3 on peripheral CD4(+) and CD8(+) T cells is involved in the development of glioma. DNA Cell Biol. 2014;33:245–50.PubMedCrossRef Han S, Feng S, Xu L, Shi W, Wang X, et al. Tim-3 on peripheral CD4(+) and CD8(+) T cells is involved in the development of glioma. DNA Cell Biol. 2014;33:245–50.PubMedCrossRef
21.
Zurück zum Zitat Li S, Peng D, He Y, Zhang H, Sun H, et al. (2014) Expression of TIM-3 on CD4+ and CD8+ T cells in the peripheral blood and synovial fluid of rheumatoid arthritis. APMIS. doi:10.1111/apm.12228 Li S, Peng D, He Y, Zhang H, Sun H, et al. (2014) Expression of TIM-3 on CD4+ and CD8+ T cells in the peripheral blood and synovial fluid of rheumatoid arthritis. APMIS. doi:10.​1111/​apm.​12228
22.
Zurück zum Zitat Ju Y, Hou N, Meng J, Wang X, Zhang X, et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol. 2010;52:322–9.PubMedCrossRef Ju Y, Hou N, Meng J, Wang X, Zhang X, et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol. 2010;52:322–9.PubMedCrossRef
23.
Zurück zum Zitat Rong YH, Wan ZH, Song H, Li YL, Zhu B, et al. Tim-3 expression on peripheral monocytes and CD3+CD16/CD56+natural killer-like T cells in patients with chronic hepatitis B. Tissue Antigens. 2014;83:76–81.PubMedCrossRef Rong YH, Wan ZH, Song H, Li YL, Zhu B, et al. Tim-3 expression on peripheral monocytes and CD3+CD16/CD56+natural killer-like T cells in patients with chronic hepatitis B. Tissue Antigens. 2014;83:76–81.PubMedCrossRef
24.
Zurück zum Zitat Wu W, Shi Y, Li J, Chen F, Chen Z, et al. Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection. Virol J. 2011;8:113.PubMedCentralPubMedCrossRef Wu W, Shi Y, Li J, Chen F, Chen Z, et al. Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection. Virol J. 2011;8:113.PubMedCentralPubMedCrossRef
Metadaten
Titel
Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma
verfasst von
Taiwu Xiao
Li Zhang
Lei Chen
Guozhen Liu
Zhenjun Feng
Lei Gao
Publikationsdatum
01.08.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2080-0

Weitere Artikel der Ausgabe 8/2014

Tumor Biology 8/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.